诊断性内镜切除治疗浅表食管癌的技术可行性与肿瘤学安全性
单机构回顾性队列研究纳入2008年7月至2014年6月135例临床T1a-M3N0M0、T1b-SM1N0M0和T1b-SM2N0M0原发性食管癌患者,排除8例以放化疗为首治者后,127例分为直接食管切除术组(n=54)和直接内镜切除组(n=73)。诊断性内镜切除未对食管切除术后的手术结局、无病生存和总生存产生负面影响,约20%的cM3-SM2N0M0患者可能通过诊断性内镜切除避免追加治疗包括食管切除术。
要点
- 诊断性内镜切除后无需要外科干预的不良事件。
- 诊断性内镜切除对食管切除术后的手术结局、无病生存和总生存无负面影响。
- 直接内镜切除组中14例(19.2%)达到治愈性切除。
核心结论
- 对于cM3-SM2食管癌,无论是否后续行食管切除术,诊断性内镜切除在手术和肿瘤学方面均可行且安全。
- 约20%的cM3-SM2N0M0患者可能通过诊断性内镜切除避免追加治疗包括食管切除术。
研究设计与样本
- 单机构回顾性队列研究,时间范围为2008年7月至2014年6月。
- 期间共有135例临床T1a-M3N0M0、T1b-SM1N0M0和T1b-SM2N0M0原发性食管癌患者被转诊至该科。
- 排除8例以放化疗为首治且病理资料不足者,其余127例分为直接食管切除术组(n=54)和直接内镜切除组(n=73)。
主要发现
- 全部127例患者的3年总生存率为95.7%,3年无病生存率为87.6%。
- 内镜切除后未观察到需要外科干预的不良事件。
- 诊断性内镜切除对食管切除术后的手术结局、无病生存和总生存无负面影响。
- 直接内镜切除组中14例(19.2%)接受了治愈性切除;直接食管切除术组中11例(20.4%)为pT1a期、无淋巴血管侵犯且无病理性淋巴结转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Active use of endoscopic resection (ER) for cM3-SM2 esophageal cancer may enable sufficient extent of esophageal resection and help determine the need for lymph node dissection based on histopathologic findings. However, ER preceding esophagectomy may have an adverse impact on outcomes. This study was designed to determine the technical feasibility and oncologic safety of diagnostic ER. METHODS: A single-institution retrospective cohort study was performed between July 2008 and June 2014. During this period, 135 consecutive patients with clinical T1a-M3N0M0, T1b-SM1N0M0, and T1b-SM2N0M0 primary esophageal cancer were referred to our division. Eight patients who underwent chemoradiotherapy as primary treatment were excluded because of inadequate pathologic findings. Based on oncologic and physical factors, we categorized the remaining 127 patients into 2 groups: primary esophagectomy (n = 54) and primary ER (n = 73). RESULTS: In all 127 patients, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 95.7% and 87.6%, respectively. No adverse event requiring surgical intervention was observed after ER. Diagnostic ER had no negative impact on surgical outcomes, DFS, and OS after esophagectomy. Fourteen patients (19.2%) of those who received primary ER underwent curative resection, whereas 11 (20.4%) who had pT1a disease, no lymphovascular invasion, and no pathologic lymph node metastasis underwent primary esophagectomy. CONCLUSIONS: Diagnostic ER for cM3-SM2 esophageal cancer with or without subsequent esophagectomy was feasible and safe, not only from a surgical perspective but also an oncologic perspective. Approximately 20% of cM3-SM2N0M0 patients can potentially avoid undergoing additional treatment including esophagectomy using diagnostic ER.
引用
- Takeuchi M, Suda K, Hamamoto Y, et al. Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointest Endosc. 2018. PMID: 29750982. doi:10.1016/j.gie.2018.04.2361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。